For copycat drugmaker Alvogen and British Big Pharma AstraZeneca, the cost of allegedly stalling generics to AZ’s cancer drug Zoladex in Korea is just $1.82 million, or 2.6 billion Korean won.
A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval next year.
A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval next year.
A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval next year.
The Anglo-Swedish company will cut the positions from the site by 2020, with a consultation on the process initiated yesterday, a workers union claimed.
AstraZeneca sells 3 drugs for $350M upfront
AstraZeneca Plc Chief Executive Officer Pascal Soriot said the lack of progress in negotiations between the U.K. and the European Union on their future ties is worrying, and could hinder the drugmaker’s exports to foreign markets after Brexit.
AstraZeneca has announced plans to invest a multi-million sum into its £150m facility in Macclesfield, Chesire, UK – a move which the company said is “part of our ongoing investment in the UK”.
AstraZeneca has said it will wait to see how Brexit negotiations progress before deciding whether to make mid-to-large scale manufacturing investments in the UK.
AstraZeneca announced that it has sold Zoladex’s (goserelin acetate implant) commercial rights in the US and Canada to TerSera Therapeutics. The deal is broken down into an up-front payment of $250 million, with a further $70 million dependent on sales-related milestones.